Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced ...

- Findings support advancement of ZL-6201 into Investigational New Drug (IND)-enabling studies in 2025 as a potential first-in-class and best-in-class antibody-drug conjugate (ADC) treatment for ...

Sutro Biopharma, Inc. announced a strategic shift focusing on its next-generation exatecan and dual-payload antibody drug conjugate (ADC) programs, deprioritizing the development of luveltamab ...

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...

Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.

Sutro Biopharma, Inc. announced a strategic shift in its focus towards its next-generation antibody drug conjugate (ADC) portfolio following a strategic review, reprioritizing its pipeline to ...

- Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in ...

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement with ...